Considerable progress has been made in prostate cancer immunotherapy over the last year, and two agents have completed phase III testing. This review will discuss the most promising immune-directed strategies in development for prostate cancer, outlining interventions that mitigate tumor-induced tolerance and highlighting several combination immunotherapy approaches.
Introduction
Cancer immunotherapy refers broadly to approaches that attempt to treat cancer by activating an immune response against malignant cells while overcoming tumor-induced tolerance. Although prostate cancer has not traditionally been thought of as a disease amenable to immunedirected therapies (such as renal cell cancer or melanoma), this notion has recently been challenged for several reasons. First, prostate cancer is a slow-growing disease [1] that may allow a stimulated immune system the necessary time to generate an antitumor response and to overcome immunosuppressive factors. Second, recent evidence suggests that prostate cancer is more immunogenic that previously recognized, having the ability to induce spontaneous autoantibodies [2] . Third, both proteomic and microarray studies of prostate cancer progression have identified several relatively tissue-specific proteins that may serve as tumor antigens [3, 4] . Finally, abundant laboratory data suggest that antitumor immune responses can be elicited against prostate cancer, especially when active immunotherapy is combined with approaches that mitigate tolerance: for example, immune checkpoint blockade, androgen ablation, or radiotherapy [5, 6] .
For these reasons, and because of the generally favorable safety profile of immunotherapy, there are currently multiple immunological strategies in clinical development for prostate cancer ( Table 1 ). Those that have generated the most interest in recent years include the GVAX allogeneic recombinant whole cell platform, the Sipuleucel-T (Provenge) autologous prostatic acid phosphatase (PAP)-loaded dendritic cell product, the Prost-Vac poxviral vector vaccine, a PAP-encoding DNA vaccine, and approaches that inhibit the immune checkpoints CTLA-4 (cytotoxic T-lymphocyte-associated antigen-4) and PD-1 (programmed death-1). This review will discuss these and other immunological strategies, outlining interventions aiming to abrogate immune toler-ance, and highlighting approaches involving combinations of immunotherapy with conventional therapies.
Tumor cell vaccines
One immunological approach with potential promise for treating prostate cancer involves the use of allogeneic prostate cancer cells as immunotherapy vectors. As cancer cells themselves are generally not immunogenic, antitumor immunity may be induced by using cancer cells engineered to express a proinflammatory cytokine or administered together with a potent immune stimulator. To this end, prostate GVAX is a cancer immunotherapy composed of two allogeneic prostate cancer cell lines (PC3 and LNCaP), genetically modified through adenoviral transfer to secrete granulocyte macrophage-colonystimulating factor (GM-CSF) and irradiated to prevent further cell division [7] . The advantage of this whole cellbased approach is that the vaccine can be manufactured in large quantities and multiple tumor antigens can be targeted simultaneously.
Two single-arm phase II studies in men with asymptomatic metastatic castration-resistant prostate cancer (CRPC) showed promising antitumor effects for prostate GVAX: one revealing an overall survival of 26.2 months and the other demonstrating an overall survival ranging from 20.0 to 29.1 months depending on the dose [8, 9] . In both studies, the proportion of patients generating antibody responses to one or both cell lines increased with the dose of vaccine given, and no dose-limiting or autoimmune toxicities were observed. Common adverse events included injection-site erythema, fatigue, malaise, and myalgias/arthralgias. On the basis of these preliminary findings, two large randomized phase III studies of GVAX immunotherapy (VITAL-1 and VITAL-2) were initiated. VITAL-1 enrolled 626 men with asymptomatic chemotherapy-naive CRPC and randomized them to GVAX or docetaxel/prednisone, with the primary endpoint being overall survival [10] [the final analysis of the phase III VITAL-1 trial, after 279 out of 626 enrolled patients had died, showed that this study was unlikely to meet its primary (survival) endpoint]. VITAL-2 was designed to enroll 600 patients with symptomatic metastatic CRPC, randomizing them to standard docetaxel/prednisone or docetaxel/GVAX [11] . Both trials were terminated early: VITAL-1 because of data from an unplanned and potentially underpowered interim analysis suggesting that the overall survival improvements initially hypothesized were unlikely to be seen and VITAL-2 because of an apparent increased mortality in the docetaxel/GVAX arm [10,11]. The mechanism for this imbalance in deaths remains unexplained, but it did not seem to result from excess toxicity in the immunotherapy arm. Although it remains theoretically possible that longer follow-up of these studies could reveal a late treatment effect of GVAX, further commercial development of this platform has been discontinued by the manufacturer.
Dendritic cell vaccines
A second approach to prostate cancer immunotherapy involves the use of autologous dendritic cells to create a personalized cancer vaccine. Sipuleucel-T (Provenge) is an immunotherapy product manufactured by collecting peripheral blood mononuclear cells from patients (via leukapheresis) and co-incubating them with a proprietary protein that couples GM-CSF with the target antigen: prostatic acid phosphatase [12] . PAP was chosen because of its cell membrane localization and more importantly because dendritic cell vaccination against PAP can break tolerance and induce autoimmunity in preclinical models [13] . This platform has the theoretical advantage of removing antigen-presenting cells from an immunosuppressive environment as the cells are activated. In addition, use of a discrete target antigen facilitates immune monitoring. Although production of large-scale quantities of individually tailored vaccine can be challenging, this immunotherapy is well tolerated. Minimal infusion-related fevers and tremors/rigors are the predominant toxicities.
Several clinical trials assessing Sipuleucel-T have been reported. In a randomized phase II/III trial comparing Sipuleucel-T and placebo in 127 asymptomatic men with metastatic CRPC [14 ] , there was no significant difference CTLA-4, cytotoxic T lymphocyte-associated antigen-4; GM-CSF, granulocyte macrophage-colony-stimulating factor; PAP, prostatic acid phosphatase; PD-1, programmed death-1; PSA, prostate-specific antigen.
in the time to disease and pain progression (P ¼ 0.052). In this study, patients randomized to placebo could cross over to receive the active vaccine upon progression, whereas those randomized to the vaccine were treated at their physician's discretion after progression. This postprogression management was not part of the initial study protocol and was not prospectively controlled. Although the trial did not meet its primary endpoint, 3-year survival data suggested a significant improvement for men in the Sipuleucel-T arm (P ¼ 0.01) [14 ] . A second phase II/III trial that randomized 98 men with asymptomatic CRPC to either Sipuleucel-T or placebo also failed to show a statistically significant improvement in time to progression and did not demonstrate an overall survival advantage at 3 years (P ¼ 0.33) [15] . Encouragingly, a post hoc-pooled analysis of these two trials (n ¼ 225) demonstrated a survival advantage for the intervention group, with median survival being 18.9 months in the placebo arm and 23.2 months in the Sipuleucel-T arm (hazard ratio 1.5; P ¼ 0.01) [16 ] . Nevertheless, because overall survival was not the primary endpoint in either trial, the US Food and Drug Administration (FDA) did not grant approval of Sipuleucel-T based on these results and requested further data in support of the efficacy claim.
Ongoing at the time of initial FDA review of Sipuleucel-T was a multicenter phase III randomized, double-blind, placebo-controlled study (IMPACT) powered to assess overall survival as its primary endpoint. The initial results of this trial, which accrued a total of 512 patients, were recently reported. These data showed that Sipuleucel-T conferred a modest but real survival advantage compared with placebo in men with metastatic CRPC (median survival 25.8 versus 21.7 months; hazard ratio 0.78; P ¼ 0.03) [17] (this was the first randomized phase III trial to demonstrate a survival benefit for an immunotherapy approach in men with metastatic prostate cancer).
Three-year survival was also improved by 38% with Sipuleucel-T compared with placebo (31.7 versus 23.0%). Interestingly, neither prostate-specific antigen (PSA) nor objective radiological responses were observed. As the FDA examines the data from this trial, the medical community eagerly awaits a potential approval decision. Of note, in all three of the above trials, the comparator arm was a placebo. Although a placebo comparator might seem unwarranted given that docetaxel chemotherapy is FDA approved for metastatic CRPC, it must be appreciated that these trials enrolled only asymptomatic men, and controversy exists regarding the optimal timing of chemotherapy in metastatic prostate cancer [18] .
Viral vector vaccines
A third immunological approach for prostate cancer involves the use of viral vectors, in particular, attenuated vaccinia viruses. These vectors have the advantage of being able to deliver relatively large target payloads and are fairly straightforward to synthesize [19] . Early in the development of vaccinia-based vectors, it was observed that additional immunization did not seem to augment immunity against the targeted antigen, but rather at the viral components of the vector itself. Thus, a heterologous prime-boost strategy was adopted, in which both vaccinia and fowlpox vectors incorporating PSA were synthesized. In a randomized phase II trial, it was shown that vaccinia priming, followed by a series of fowlpox booster treatments resulted in an optimal immune response as revealed by correlative studies [20] . In addition, long-term follow-up of that trial suggested a trend toward increased progression-free survival in men with advanced prostate cancer treated with the optimal immunotherapy sequence [21] . This vaccinia prime/fowlpox boost strategy exemplifies the notion of a heterologous prime-boost immunization scheme; unfortunately, heterologous strategies are not employed often in cancer immunotherapy.
Poxviral vectors have been further refined using a platform of recombinant PSA inserted into fowlpox and vaccinia vectors (designated rF-PSA and rV-PSA, respectively). ProstVac consists of these constructs of rF-PSA and rV-PSA and also contains a triad of costimulatory transgenes known as TriCom (intercellular adhesion molecule-1, B7-1, and leukocyte functionassociated antigen 3) that serve to augment the immune response [22] . A phase I study using a priming dose of ProstVac followed by a booster dose 4 weeks later in chemotherapy-naive patients with CRPC produced minimal toxicities (injection site reactions, pruritus, fevers/ chills, fatigue) and resulted in PSA stabilization lasting 8 weeks in 40% of men [23] . A randomized, double-blind phase II trial of ProstVac (one priming dose, then six boosts over 24 weeks) versus empty vector in 122 men with metastatic CRPC initially failed to show a significant difference in the primary endpoint of progression-free survival between treatment arms (P ¼ 0.56) [24] . However, updated 3-year results of this trial revealed an overall survival benefit in the ProstVac arm (median survival 24.5 versus 16.0 months; P ¼ .016) [25 ] . As survival was a secondary endpoint in this trial, these findings should be considered hypothesis generating. Nevertheless, a randomized phase III study using docetaxel with or without ProstVac as first-line therapy for men with metastatic CRPC is expected to open in 2010.
DNA vaccines
A fourth type of prostate cancer immunotherapy focuses on DNA-based constructs that serve to activate specific antitumor immune responses. This approach is exemplified by a phase I/II study using a plasmid DNA vaccine (pTVG-HP) directed against PAP, administered to men with biochemically recurrent nonmetastatic prostate cancer [26 ] . As with other immunotherapies, this vaccine was well tolerated and appeared to result in both T-cell and antibody responses to the target antigen: PAP. An increase in the median PSA doubling time was noted (corresponding to a slowing in the rate of PSA rise), although the clinical significance of this change is debatable. Given the small number of patients enrolled, a correlation between clinical parameters (e.g., PSA-doubling time) and immunological readouts was not evident, but the available data support the notion that this DNA vaccine induced detectable responses in early-stage prostate cancer. As illustrated here, one of the major challenges in cancer vaccine development has been the establishment of a clear relationship between induction of antigen-specific T-cell responses and clinical outcomes, and it is conceivable that a larger trial using this same vaccine could provide such data. A second challenge is the selection of appropriate target antigens from the broad spectrum available; this trial highlights the utility of the DNA vaccine approach to facilitate the systematic evaluation of additional prostate-restricted antigens.
Immune modulators
Due to ongoing host immunological pressures on evolving tumors, cancers have developed several mechanisms to escape immune surveillance, effectively inducing a relative state of immune tolerance [5, 27] . For example, tumors have been shown to induce expansion of CD4 þ CD25 þ regulatory T cells (Tregs), leading to delayed recognition of immunogenic cancers [28, 29] . Importantly, elimination of these Tregs often elicits potent antitumor responses leading to tumor control in preclinical models. Another immune-modulating approach that has recently emerged is blockade of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) using monoclonal antibodies. CTLA-4 is a cell surface molecule on T lymphocytes that functions as a negative regulator of T-cell activation, leading to attenuation of T-cell responses against tumor cells [30] . CTLA-4 blockade has previously been shown to potentiate T-cell effects and induce tumor rejection in murine models [31] . Several trials using the anti-CTLA-4 antibody, ipilimumab, have been conducted in men with metastatic CRPC. These include a phase I/II study of ipilimumab monotherapy [32 ] , as well as a phase I dose-escalating study combining ipilimumab with GM-CSF [33 ]. Encouragingly, PSA declines as well as radiological responses were observed in both trials. Another phase I study testing the combination of ipilimumab and GVAX also demonstrated objective clinical responses at upper dose levels [34 ] . A multicenter randomized phase III study in docetaxel-refractory patients is currently underway and aims to examine the combination of ipilimumab with radiation therapy in men with bone metastases. Common side-effects of ipilimumab include fatigue, rash, pruritus, nausea, constipation, and weight loss. Immunological toxicities (resulting from immune system activation) include adrenal insufficiency, hepatitis, and autoimmune colitis.
Another co-inhibitory receptor molecule expressed on activated T lymphocytes that functions as an immune checkpoint is programmed death-1 (PD-1). When PD-1 is bound by its ligand, T-cell activation and proliferation are inhibited, resulting in suppression of antitumor immune responses [35] . Expression of the PD-1 ligand has been described in a variety of human malignancies including prostate cancer, leading to decreased tumorspecific immunogenicity [36] . In addition, the majority of prostate-infiltrating CD8 þ T cells appear to express PD-1 [37 ] , suggesting that inhibition of this checkpoint might be effective in prostate cancer. In many human tumors, expression of the PD-1 ligand correlates with a poorer prognosis. A phase I trial using MDX-1106 (a fully human anti-PD-1 monoclonal antibody) in patients with refractory metastatic solid tumors (including metastatic CRPC) has recently been completed [38 ] . This agent appeared to be well tolerated, with common toxicities being subclinical hypothyroidism and low-grade autoimmune arthritis. Radiographic responses were observed in a variety of tumors including melanoma, renal cell cancer, lung cancer, and colon cancer. A phase Ib study of MDX-1106 in patients with selected refractory/relapsed malignancies is currently underway; this trial will enroll 16 men with CRPC in an expansion phase [39] . A related agent, MDX-1105 (a monoclonal antibody that blocks the PD-1 ligand B7-H1), has also entered phase I clinical trials.
Conclusion
In the last few years, great strides have been made in the clinical development of immunological therapies for prostate cancer, leading to the identification of an agent (Sipuleucel-T) that extends survival in patients with metastatic CRPC. Although the potential FDA approval of this modality is encouraging, other efforts to improve patient outcomes using different immunotherapy platforms have been met with less success. A number of barriers to effective prostate cancer immunotherapy are increasingly being recognized and appear to be most pronounced in patients with advanced disease and high tumor burden. These include the presence of circulating immunosuppressive cytokines, the activation of regulatory T cells, and the existence of immune checkpoints mediated by cell surface molecules such as CTLA-4 and PD-1.
Interestingly, although few (if any) objective responses have been reported in the vaccine trials reviewed here, tumor shrinkage and PSA responses occur with some frequency in patients treated with agents that block immunological checkpoints. This observation, although clearly preliminary, suggests a new paradigm. Instead of conceptualizing combination immunotherapy as the addition of secondary agents to vaccines, perhaps a more appropriate framework would be to place checkpoint blockade at the center of combination immunotherapy. As such, combination approaches in which additional agents or treatments (including vaccines) are added in a rational manner to checkpoint inhibitors may be a more appropriate paradigm. Perhaps it is time to move from a vaccine-centric world to a checkpoint-centric one. Regardless of the operational framework employed, it has become clear that immunotherapy may play a role in prostate cancer treatment and that further clinical investigation will be required to determine the optimal strategy for clinical success.
